Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min

A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or nevirapine was conducted to evalu...

Full description

Bibliographic Details
Main Authors:	Ross, LL, Walker, AS, Lou, Y, Tenorio, AR, Gibb, DM, Double, J, Gilks, C, McCoig, CC, Munderi, P, Musoro, G, Kityo, CM, Grosskurth, H, Hakim, J, Mugyenyi, PN, Cutrell, A, Perger, T, Shaefer, MS
Format:	Journal article
Language:	English
Published:	Public Library of Science 2019

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min

Similar Items